Loading
A phase 1/2 trial of Glecirasib in non-small-cell lung cancer, run by Allist Pharmaceuticals, Inc., active and no longer recruiting.
A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China is a phase 1/2 interventional study registered as NCT05009329 by Allist Pharmaceuticals, Inc., with 315 participants enrolled, started 2021-07-26 and due to reach its primary completion in 2026-08. Interventions recorded: JAB-21822.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Shanghai Allist Pharmaceuticals, Glecirasib, KRAS & RAS inhibitors, Small-molecule kinase inhibitors and the tag pipeline.
Shares Shanghai Allist Pharmaceuticals, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Shanghai Allist Pharmaceuticals, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Glecirasib, KRAS G12C-mutant non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Shanghai Allist Pharmaceuticals, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/